Literature DB >> 9687578

Role of the extracellular domains of the cholecystokinin receptor in agonist binding.

S Silvente-Poirot1, C Escrieut, S A Wank.   

Abstract

The cholecystokinin (CCK) receptor types A and B (CCKAR and CCKBR) are G protein-coupled receptors with approximately 50% amino acid identity; both have high affinity for the sulfated CCK octapeptide (CCK-8), whereas only the CCKBR has high affinity for gastrin. Previously, we identified five amino acids in the second extracellular loop (ECL) of the CCKBR that were essential for gastrin selectivity. Subsequent mutagenesis of one of these five amino acids (H207F) resulted in the loss of radiolabeled CCK-8 binding. CCK-8 stimulated total inositol phosphate accumulation in COS-1 cells transiently expressing the CCKBR-H207F with full efficacy and a 3044-fold reduced potency, which suggests that the loss of radioligand binding was caused by a loss in affinity. Alanine scanning mutagenesis was performed on the amino terminus near the top of transmembrane domain I (TMI) and on ECL1, two extracellular domains implicated in ligand binding by previous mutagenesis studies. 125I-Bolton-Hunter-CCK-8 binding to mutant receptors transiently expressed in COS-1 identified one nonconserved amino acid, R57A, at the top of TMI that caused a 21-fold reduction in CCK-8 affinity and four conserved amino acids, N115A, L116A, F120A and F122A, in the ECL1 that caused a 15.6-, 6-, 440-, and 8-fold reduction in affinity or efficacy. Alanine substitution of the equivalent amino acids in the CCKAR corresponding to each of the five amino acids in ECL1 and ECL2 affecting CCK-8 affinity for the CCKBR revealed only two mutations, L103A and F107A, that decreased CCK-8 affinity (68- and 2885-fold, respectively). These data suggest that CCK-8 interacts at multiple contact points in the extracellular domains of CCK receptors and that the CCKAR and CCKBR have distinct binding sites despite their shared high affinity for CCK-8.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9687578     DOI: 10.1124/mol.54.2.364

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  14 in total

1.  Arginine 197 of the cholecystokinin-A receptor binding site interacts with the sulfate of the peptide agonist cholecystokinin.

Authors:  V Gigoux; B Maigret; C Escrieut; S Silvente-Poirot; M Bouisson; J A Fehrentz; L Moroder; D Gully; J Martinez; N Vaysse; A D Fourmy
Journal:  Protein Sci       Date:  1999-11       Impact factor: 6.725

2.  Importance of extracellular loop one of the neuropeptide S receptor for biogenesis and function.

Authors:  Stewart D Clark; Ha T Tran; Joanne Zeng; Rainer K Reinscheid
Journal:  Peptides       Date:  2009-10-27       Impact factor: 3.750

3.  Role of AMP-18 in oral mucositis.

Authors:  Peili Chen; Mark Lingen; Stephen T Sonis; Margaret M Walsh-Reitz; F Gary Toback
Journal:  Oral Oncol       Date:  2011-07-06       Impact factor: 5.337

4.  The molecular basis for high affinity of a universal ligand for human bombesin receptor (BnR) family members.

Authors:  Hirotsugu Uehara; Simon J Hocart; Nieves González; Samuel A Mantey; Tomoo Nakagawa; Tatsuro Katsuno; David H Coy; Robert T Jensen
Journal:  Biochem Pharmacol       Date:  2012-07-22       Impact factor: 5.858

5.  Development of a highly selective allosteric antagonist radioligand for the type 1 cholecystokinin receptor and elucidation of its molecular basis of binding.

Authors:  Maoqing Dong; Ashton M Vattelana; Polo C-H Lam; Andrew J Orry; Ruben Abagyan; Arthur Christopoulos; Patrick M Sexton; David R Haines; Laurence J Miller
Journal:  Mol Pharmacol       Date:  2014-10-15       Impact factor: 4.436

6.  The role of amino acids in extracellular loops of the human P2Y1 receptor in surface expression and activation processes.

Authors:  C Hoffmann; S Moro; R A Nicholas; T K Harden; K A Jacobson
Journal:  J Biol Chem       Date:  1999-05-21       Impact factor: 5.157

7.  Molecular basis for the selectivity of the mammalian bombesin peptide, neuromedin B, for its receptor.

Authors:  Nieves González; Tomoo Nakagawa; Samuel A Mantey; Veronica Sancho; Hirotsugu Uehara; Tatsuro Katsuno; Robert T Jensen
Journal:  J Pharmacol Exp Ther       Date:  2009-07-23       Impact factor: 4.030

8.  Molecular basis for high affinity and selectivity of peptide antagonist, Bantag-1, for the orphan BB3 receptor.

Authors:  Taichi Nakamura; Irene Ramos-Álvarez; Tatiana Iordanskaia; Paola Moreno; Samuel A Mantey; R T Jensen
Journal:  Biochem Pharmacol       Date:  2016-06-23       Impact factor: 5.858

9.  Direct demonstration of unique mode of natural peptide binding to the type 2 cholecystokinin receptor using photoaffinity labeling.

Authors:  Maoqing Dong; Laurence J Miller
Journal:  Peptides       Date:  2013-06-14       Impact factor: 3.750

10.  Molecular basis for agonist selectivity and activation of the orphan bombesin receptor subtype 3 receptor.

Authors:  Nieves Gonzalez; Simon J Hocart; Sergio Portal-Nuñez; Samuel A Mantey; Tomoo Nakagawa; Enrique Zudaire; David H Coy; Robert T Jensen
Journal:  J Pharmacol Exp Ther       Date:  2007-11-15       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.